Answers are grounded in this paper and cite their sources.
Allogeneic hematopoietic stem cell transplantation (HSCT) has been used as effective therapy for selected non-malignant diseases including aplastic anemia, primary immunodeficiencies and inherited metabolic diseases. Although the therapeutic elements such as donor selection, preparative regimen and GVHD prophylaxis are mutual between HSCT for malignant diseases and HSCT for non-malignant diseases, deciding criterion and adjustment of agents are different. Related donor candidate who diagnosed as disease-carrier should be excluded from donor in certain inherited diseases. Preparative regimens for non-malignant diseases should have enough immunosuppressive effect that enables donor-cell engraftment without loss of fertility. However, even the optimum-conditioning regimen for aplastic anemia is not established until now and under elaboration. Major problems in the HSCT for non-malignant diseases have been considered high rate of graft rejection and mixed hematopoietic chimerism, new autoimmune diseases including autoimmune hemolytic anemia and autoimmune thrombocytopenia become notable complications after cord blood transplantation in recent years.
No takes yet. Share an insight, caveat, or question.
Hiromasa Yabe (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: